Ann: Shareholder Update Q3 2018, page-13

IMO, With both leg and foot ulcers the market is in the billions $, just in the US and Europe, and not many players. China, India, Russia's middle class will be having the same medical issues the west have and open new markets. I am still not confident they will get it to market, particularly if the data is very positive and a DFU study is confirmed. The other applications are good but they will take a back seat to VLU/DFU in the short term. The big US pharmas should gobble this up and won't mind paying 300-400m for the pleasure. I cant see the Directors knocking back that sort of money. The elephant in this space is J&J and this would compliment their other products / treatment, and they have huge global distribution and supply already in place. This really could be a huge cash-cow as the treatment is not confined to a small target audience and manufacturing is transferable to any durastiction anywhere in the world. Ive slowly averaged down from the heady days of TIS and have been sneaking a few here and there over the last few months. Ive broken all my own rules over this one, so if it works, as I hope it will, I can pat myself on the back and tell the wife what a genius I am. If it fails I will just not tell the missus and work until I'm 100.